Infusystem Hld Stock Price, News & Analysis

InfuSystem (NYSE:INFU) reported third quarter 2025 results with net revenues of $36.5 million, up 3.3% year-over-year, and net income of $2.3 million (+25%).

Adjusted EBITDA (non-GAAP) was $8.3 million, up 6% with a margin of 22.8%. Gross profit rose 9.3% to $20.8 million and gross margin improved to 57.1%. Year-to-date net operating cash flow was $17.3 million, up 38%.

The Patient Services segment grew 7.6% to $22.4 million (wound care +115% driven by new PCD supplier), while Device Solutions declined 2.9% to $14.1 million. Company liquidity was $54.6 million. Management reaffirmed full-year 2025 guidance of net revenue growth 6–8% and Adjusted EBITDA margin ≥20%.

InfuSystem (NYSE American: INFU) will report third quarter 2025 financial results on Tuesday, November 4, 2025 before the market opens.

The company will host an investor conference call on November 4, 2025 at 9:00 a.m. Eastern Time; dial-in numbers are (833) 366-1127 or (412) 902-6773, and a live webcast will be available in the Investors section at https://ir.infusystem.com/.

A replay will be available at https://ir.infusystem.com/ for 90 days or by calling (855) 669-9658 or (412) 317-0088 with replay access code 7148856 through Tuesday, November 11, 2025. InfuSystem is a national health care service provider operating Patient Services and Device Solutions platforms and maintains Centers of Excellence in multiple U.S. states and Ontario, Canada.

InfuSystem Holdings (NYSE American: INFU), a national healthcare service provider specializing in outpatient care and durable medical equipment services, has announced its participation in the 4th Annual ROTH Healthcare Opportunities Conference. CEO Carrie Lachance and CFO Barry Steele will attend the conference on October 9, 2025, at the Metropolitan Club in New York City.

The company operates under two main platforms: Patient Services (including Oncology, Pain Management, and Wound Therapy) and Device Solutions. Management will be available for one-on-one virtual meetings throughout the conference day, which investors can arrange through their conference representative or Lytham Partners.

InfuSystem Holdings (NYSE American:INFU) reported strong Q2 2025 financial results with record net revenues of $36.0 million, up 7% year-over-year. The company achieved significant improvements across key metrics, including a 262% increase in net income to $2.6 million and a 32% rise in Adjusted EBITDA to $8.0 million.

Patient Services revenue grew 6% to $21.5 million, while Device Solutions revenue increased 8% to $14.5 million. Gross margin expanded by 5.7% to 55.2%, and Adjusted EBITDA margin improved by 4.3% to 22.3%. The company completed $3.5 million in stock repurchases during the quarter.

InfuSystem updated its 2025 guidance, lowering revenue growth expectations to 6-8% from 8-10%, but raising its Adjusted EBITDA margin forecast to 20% or higher, representing a 120 basis point increase over 2024.

InfuSystem Holdings (NYSE American: INFU), a national healthcare service provider specializing in outpatient care and durable medical equipment, has scheduled its second quarter 2025 financial results announcement for August 5, 2025, before market open.

The company will host a conference call at 9:00 a.m. Eastern Time on the same day to discuss the results. Investors can participate via phone or webcast, with a replay available until August 12, 2025.

InfuSystem operates through two platforms: Patient Services (including Oncology, Pain Management, and Wound Therapy) and Device Solutions, with operations centers across the US and Canada.

InfuSystem Holdings (NYSE American: INFU) reported strong Q1 2025 financial results with record net revenues of $34.7 million, up 9% year-over-year. The company's Patient Services revenue increased 12% to $20.8 million, while Device Solutions revenue grew 4% to $13.9 million. Despite posting a net loss of $0.3 million ($0.01 per share), the company showed significant improvement from prior year's loss of $1.1 million. Adjusted EBITDA surged 64% to $6.3 million, with margin expanding to 18.2%. The company conducted stock repurchases totaling $3.0 million and maintained strong liquidity of $47.6 million. InfuSystem reaffirmed its 2025 guidance, projecting 8-10% revenue growth. The quarter also marked a leadership transition, with CEO Richard DiIorio stepping down and COO Carrie Lachance preparing to take the helm.

InfuSystem Holdings (NYSE American: INFU), a leading national healthcare service provider, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, before market open. The company will host a conference call at 9:00 a.m. Eastern Time on the same day to discuss the results.

InfuSystem operates under a two-platform model: Patient Services, which includes Oncology, Pain Management, and Wound Therapy businesses, providing clinic-to-home healthcare solutions; and Device Solutions, which supports the Patient Services platform through direct payer rentals, pump and consumable sales, and biomedical services. The company maintains Centers of Excellence across Michigan, Kansas, California, Massachusetts, Texas, and Ontario, Canada.

InfuSystem Holdings (NYSE American: INFU) announced a planned CEO transition, with current President and COO Carrie Lachance set to succeed Richard DiIorio as Chief Executive Officer effective May 19, 2025. DiIorio will remain available as an advisor to support the transition.

Lachance, who joined the company in 2010, has served in various leadership roles including Senior Vice President of Clinical and Customer Services and Territory Sales Manager. She has been President since 2021, COO since 2019, and a board member since 2021.

The company reaffirmed its full-year 2025 guidance, projecting revenue growth of 8-10% and an Adjusted EBITDA margin exceeding 18.8%, surpassing 2024's performance despite planned investments in business applications.

InfuSystem Holdings (NYSE: INFU) reported strong financial results for Q4 and full year 2024, achieving record net revenues of $134.9 million, up 7% year-over-year. The company's performance showed significant improvements across key metrics:

Patient Services revenue reached $80.4 million (+5%) while Device Solutions revenue hit $54.5 million (+11%). Notable achievements include:

• Record operating cash flow of $20.5 million (+82%)
• Adjusted EBITDA of $25.3 million (+13%)
• Net income of $2.3 million ($0.11 per diluted share)
• Gross margin improved to 52.2% (+2%)

For 2025, InfuSystem projects revenue growth of 8-10% with Adjusted EBITDA margins expected to exceed 2024's 18.8%, despite planned technology upgrade investments of approximately $2.5 million.